Anti-HEMGN antibody produced in rabbit

HEMGN (hemogen) is a hematopoietic-specific nuclear protein expressed in hematopoietic tissues. Specifically, it is expressed in the human hematopoietic tissues and cells such as adult bone marrow, CD34+ progenitor cells and leukemia cell line K562. It is located to chromosome 9q22.

Hemogen recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

HEMGN (hemogen) is mainly involved in the regulation of hematopoietic cell differentiation, proliferation, and apoptosis. It plays an important role in transcriptional regulation. It directly binds to the transcriptional regulators to control the apoptotic gene expression. It also plays an important role in the hematopoietic regulation. Promoter region of HEMGN directly binds to the homeobox transcription factor HOXB4 and promotes expansion of hematopoietic stem cells and hematopoietic progenitor cells. It has been reported that overexpression of HEMGN in cell lines restricts the expression for apoptosis and differentiation. Study proposes that HEMGN may play a regulatory role in acute myeloid leukemia (AML) and can be a new therapeutic target for the treatment of AML.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Corresponding Antigen APREST74491

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.